Core Insights - MapLight Therapeutics, Inc. has updated the expected timing for topline results from its Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule [1] Group 1: ZEPHYR Trial - The Phase 2 ZEPHYR trial is evaluating ML-007C-MA for treating schizophrenia and is expected to report topline results in Q3 2026 [2] - The ZEPHYR study is a randomized, double-blind, placebo-controlled trial enrolling approximately 300 hospitalized adult participants experiencing acute exacerbation of psychosis [2][3] - The accelerated enrollment pace in the ZEPHYR trial has allowed the company to narrow its timing guidance to Q3 2026, reflecting disciplined execution and commitment to quality [3] Group 2: IRIS Trial - The Phase 2 IRIS trial for ML-004 in autism spectrum disorder has completed enrollment, with topline results also expected in Q3 2026 [3] - The IRIS study is a double-blind, placebo-controlled trial that randomized around 160 adult and adolescent participants [3] Group 3: Company Overview - MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with central nervous system disorders [4] - The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies [4] - MapLight's discovery platform aims to identify neural circuits linked to diseases and target them for therapeutic modulation [4]
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026